Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -8.55% | -11.74% | -32.99% | -11.11% | 9.08% |
| Gross Profit | 8.55% | 11.74% | 32.99% | 11.11% | -9.08% |
| SG&A Expenses | -60.14% | -23.40% | -26.69% | 128.43% | 120.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.94% | -15.58% | -31.37% | 30.31% | 45.14% |
| Operating Income | 33.94% | 15.58% | 31.37% | -30.31% | -45.14% |
| Income Before Tax | 38.16% | 19.31% | 31.22% | -22.91% | -50.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.16% | 19.31% | 31.22% | -22.91% | -50.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.16% | 19.31% | 31.22% | -22.91% | -50.61% |
| EBIT | 33.94% | 15.58% | 31.37% | -30.31% | -45.14% |
| EBITDA | 34.12% | 15.66% | 31.50% | -30.58% | -45.50% |
| EPS Basic | 74.77% | 65.04% | 62.71% | 6.90% | -27.27% |
| Normalized Basic EPS | 74.71% | 65.08% | 62.81% | -5.05% | -27.21% |
| EPS Diluted | 74.77% | 65.04% | 62.71% | 6.90% | -27.27% |
| Normalized Diluted EPS | 74.71% | 65.08% | 62.81% | -5.05% | -27.21% |
| Average Basic Shares Outstanding | 145.16% | 130.85% | 84.44% | 32.03% | 18.35% |
| Average Diluted Shares Outstanding | 145.16% | 130.85% | 84.44% | 32.03% | 18.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |